Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 13/20 | 0.53 |
| ▸ | DPP7 | Q9UHL4 | 7/20 | 0.53 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.53 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | GLA | P06280 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2850241 | 1.00 | DPP4 (0.53) | DPP4DPP7DPP8DPP9ALDH1A1 | |
| SCHEMBL2847975 | 0.85 | DPP4 (0.65) | DPP4DPP7DPP8DPP9ALDH1A1 | |
| SCHEMBL2847977 | 0.85 | DPP4 (0.65) | DPP4DPP7DPP8DPP9ALDH1A1 | |
| SCHEMBL2854616 | 0.84 | DPP4 (0.53) | DPP4DPP7DPP8DPP9 | |
| SCHEMBL2367718 | 0.84 | DPP4 (0.60) | DPP4DPP7DPP8DPP9 | |
| SCHEMBL2862010 | 0.82 | RECQL (0.48) | DPP4DPP7DPP8DPP9ALDH1A1 | |
| SCHEMBL2862017 | 0.82 | RECQL (0.48) | DPP4DPP7DPP8DPP9ALDH1A1 | |
| SCHEMBL2852679 | 0.82 | DPP4 (0.60) | DPP4DPP7DPP8DPP9 | |
| SCHEMBL2852676 | 0.82 | DPP4 (0.60) | DPP4DPP7DPP8DPP9 | |
| SCHEMBL2854242 | 0.82 | DPP4 (0.58) | DPP4DPP7DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7790725-B2 | Thiazolidine derivatives and medicinal use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-09-07 | — | — | US | disclosed |
| US-20070259880-A1 | THIAZOLIDINE DERIVATIVES AND MEDICINAL USE THEREOF | MITSUBISHI PHARMA CORPORATION (JP) | 2007-11-08 | — | — | US | disclosed |
| US-20040259883-A1 | Thiazolidine derivative and medicinal use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2004-12-23 | — | — | US | disclosed |
| EP-1426366-A1 | THIAZOLIDINE DERIVATIVE AND MEDICINAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2004-06-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259880-A1 | THIAZOLIDINE DERIVATIVES AND MEDICINAL USE THEREOF | DPP4, DPP7, DPP3 | DPP4 1/4885DPP7 2/4885DPP8 5/4885 |
| US-20040259883-A1 | Thiazolidine derivative and medicinal use thereof | DPP4, DPP7, DPP3 | DPP4 1/4885DPP7 2/4885DPP8 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.